{"summary":"Accomplished leader in oncology translational science with extensive experience spanning discovery research, early clinical development, and registration trials; contributed to four FDA approved therapies (Zejula, Jemperli, Elahere, Fotivda); In depth knowledge of wide range of therapeutic modalities including small molecule, biologics, ADC, and radionuclide therapies; Comprehensive technical expertise in pharmacology, biomarker discovery, assay development and validation; Co-led development of an FDA approved CDx (FOLR1-2.1); Key contributor to several highly successful industry and academic collaborations; Skilled in mentoring junior scientists and building collaborative, productive teams. Consistently delivered high quality results against aggressive timelines","lastName":"Zhou","objectUrn":"urn:li:member:53465960","geoRegion":"Cambridge, Massachusetts, United States","fullName":"Yinghui Zhou","firstName":"Yinghui","currentPositions":[{"companyName":"Synnovation Therapeutics","title":"Executive Director","tenureAtCompany":{"numMonths":1},"companyUrnResolutionResult":{"employeeCountRange":"11-50","headquarters":{"geographicArea":"DE","country":"United States","city":"Wilmington","postalCode":"19803","line1":"200 Powder Mill Road"},"website":"http:\/\/www.synnovationtx.com","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/synnovationtx\/","industry":"Pharmaceutical Manufacturing"},"startedOn":{"month":5,"year":2024},"companyUrn":"urn:li:fs_salesCompany:80119777"}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAAMv02gBumn9_tEfcvYKaYmzITHzti5D4Q4,NAME_SEARCH,X_tR)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1516575491720?e=1723075200&v=beta&t=vQBCplQcY7b-zw0LM24fd4cE8IGxe6P6B5oUArTyeg4","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1516575492051?e=1723075200&v=beta&t=qSesWNHFJ7FpfpkjT43bxjIl51Bv40MSbY9-2rtcjcE","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1516575491676?e=1723075200&v=beta&t=bQOT0MNtemMbW-nrpxRt0YIFbFj8ExoXA4tdeNCiu70","height":400},{"width":450,"fileIdentifyingUrlPathSegment":"800_800\/0\/1516575504648?e=1723075200&v=beta&t=r7RFJsHajLjpjV5E7TA7koehKncXEL2RkG9SmMBHHEw","height":450}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/C4D03AQFBsfXnwKjXCQ\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Pharmaceutical Manufacturing","educations":[{"endedOn":{"year":2000},"degree":"Ph.D","eduId":38527148,"schoolUrn":"urn:li:fs_salesSchool:3196","school":"urn:li:fs_salesSchool:3196","fieldsOfStudy":["Biochemistry, Molecular Biology and Cell Biology"],"schoolName":"Northwestern University","startedOn":{"year":1994}},{"endedOn":{"year":1993},"degree":"B.S","eduId":38527174,"schoolUrn":"urn:li:fs_salesSchool:1353655","school":"urn:li:fs_salesSchool:1353655","fieldsOfStudy":["Ecology and Environmental biology"],"schoolName":"Nankai University","startedOn":{"year":1989}}],"skills":[{"numOfEndorsement":12,"name":"Drug Discovery"},{"numOfEndorsement":14,"name":"Biotechnology"},{"numOfEndorsement":18,"name":"Cancer"},{"numOfEndorsement":5,"name":"In Vitro"},{"numOfEndorsement":4,"name":"Assay Development"},{"numOfEndorsement":7,"name":"Molecular Biology"},{"numOfEndorsement":9,"name":"PCR"},{"numOfEndorsement":7,"name":"Cell Biology"},{"numOfEndorsement":17,"name":"In Vivo"},{"numOfEndorsement":6,"name":"Cell"},{"numOfEndorsement":6,"name":"Genomics"},{"numOfEndorsement":6,"name":"Clinical Development"},{"numOfEndorsement":5,"name":"Pharmacology"},{"numOfEndorsement":2,"name":"Antibodies"},{"numOfEndorsement":19,"name":"Drug Development"},{"numOfEndorsement":3,"name":"Translational Research"},{"numOfEndorsement":2,"name":"Genetics"},{"numOfEndorsement":3,"name":"DNA"},{"numOfEndorsement":2,"name":"Microarray"},{"numOfEndorsement":1,"name":"Animal Models"}],"numOfConnections":791,"patents":[{"inventors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAMv02gBumn9_tEfcvYKaYmzITHzti5D4Q4,NAME_SEARCH,X_tR)"}],"title":"Chimeric cancer models","issuer":"us"},{"inventors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAMv02gBumn9_tEfcvYKaYmzITHzti5D4Q4,NAME_SEARCH,X_tR)"}],"title":"Directed complementation","issuer":"us"}],"headline":"Head of Translational Science, Synnovation Therapeutics","courses":[],"certifications":[],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/yinghuizhou","organizations":[{"name":"ASCO","position":"Scientist member","startedOn":{"month":6,"year":2012}},{"name":"AACR","position":"Full member","startedOn":{"month":1,"year":2007}}],"location":"Cambridge, Massachusetts, United States","publications":[{"name":"Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.","publishedOn":{"month":1,"day":28,"year":2010},"publisher":"Nature Biotechnology","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAMv02gBumn9_tEfcvYKaYmzITHzti5D4Q4,NAME_SEARCH,X_tR)"}]},{"name":"Genetically Engineered Mouse Models of Human Cancer for Drug Discovery and Development","publishedOn":{"year":2005},"publisher":"The Oncogenomics Handbook: Cancer Drug Discovery and Development","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAMv02gBumn9_tEfcvYKaYmzITHzti5D4Q4,NAME_SEARCH,X_tR)"}]},{"name":"GATA-2 is required for the generation of V2 interneurons","publishedOn":{"year":2000},"publisher":"Development","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAMv02gBumn9_tEfcvYKaYmzITHzti5D4Q4,NAME_SEARCH,X_tR)"}]},{"name":"Rescue of the embryonic lethal hematopoietic defect reveals a critical role for GATA-2 in urogenital development","publishedOn":{"year":1998},"publisher":"EMBO J","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAMv02gBumn9_tEfcvYKaYmzITHzti5D4Q4,NAME_SEARCH,X_tR)"}]},{"name":"Spontaneous Genomic Alterations in a Chimeric Model of Colorectal Cancer Enable Metastasis and Guide Effective Combinatorial Therapy","description":"Colon cancer is the second most common cause of cancer mortality in the Western world with metastasis commonly present at the time of diagnosis. Screening for propagation and metastatic behavior in a novel chimeric-mouse colon cancer model, driven by mutant p53 and \u03b2-Catenin, led to the identification of a unique, invasive adenocarcinoma. Comparison of the genome of this tumor, CB42, with genomes from non-propagating tumors by array CGH and sequencing revealed an amplicon on chromosome five containing CDK6 and CDK14, and a KRAS mutation, respectively. Single agent small molecule inhibition of either CDK6 or MEK, a kinase downstream of KRAS, led to tumor growth inhibition in vivo whereas combination therapy not only led to regression of the subcutaneous tumors, but also near complete inhibition of lung metastasis; thus, genomic analysis of this tumor led to effective, individualized treatment.","publisher":"PLOS One","url":"http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0105886","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAMv02gBumn9_tEfcvYKaYmzITHzti5D4Q4,NAME_SEARCH,X_tR)"}]}],"positions":null,"posts":[{"createdAt":1715483160000,"insightId":"ae81a0bb-df33-4f06-9a58-f5469576c6d5","activityUnion":{"postActivity":{"contentSummaryUnion":{"referenceContentSummary":{"entityUrn":"urn:li:celebrateJobChange:7195257996740907008"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":97},{"type":"PRAISE","count":22},{"type":"EMPATHY","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7195257997499998208","threadUrn":"urn:li:ugcPost:7195257997499998208","reactionsCount":120,"commentsCount":65,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7195257997499998208","message":{"attributes":[{"length":24,"start":88,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:80119777"}}}],"text":"I\u2019m happy to share that I\u2019m starting a new position as Head of Translational Science at Synnovation Therapeutics!"},"entityUrn":"urn:li:ugcPost:7195257997499998208"}}},{"createdAt":1712671440000,"insightId":"b778d39f-db04-4f42-8eda-871739d83ec7","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7180589632638640128,7183464899019198464)","threadUrn":"urn:li:ugcPost:7180589632638640128","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Kristin"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7180589632638640128"}}},{"createdAt":1711552860000,"insightId":"0f5da1d9-0c1b-4523-a6fa-9d8fb4a4c67b","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7178349320063049728,7178773056897597440)","threadUrn":"urn:li:ugcPost:7178349320063049728","reactionsCount":1,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Joana!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7178349320063049728"}}},{"createdAt":1710957540000,"insightId":"19d40b0a-040a-44e5-a117-bb70c69759cc","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7175332005616783360,7176276118004473856)","threadUrn":"urn:li:ugcPost:7175332005616783360","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Mark"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7175332005616783360"}}}]}